On Tuesday, December 11, Finnegan client Eli Lilly and Company filed suit in the U.S. District of Eastern Virginia claiming the U.S. Patent and Trademark Office “acted arbitrarily in failing to extend its patent for a cancer treatment solution and methods by an additional year and a half.” The lawsuit concerns the USPTO’s patent term adjustment calculation on Eli Lilly’s U.S. Patent Number 8,114,901. Eli Lilly and Company is represented by Finnegan in this matter.